Who Exports Sirolimus from India — 97 Suppliers Behind a $14.9M Market
India's sirolimus export market is supplied by 97 active exporters who collectively shipped $14.9M across 1,244 shipments. ZYDUS LIFESCIENCES LIMITED leads with a 37.5% market share, followed by ALKEM LABORATORIES LIMITED and CADILA HEALTHCARE LIMITED. The top 5 suppliers together control 91.2% of total export value, reflecting a concentrated market structure.
Top Sirolimus Exporters from India — Ranked by Export Value
ZYDUS LIFESCIENCES LIMITED is the leading sirolimus exporter from India, holding a 37.5% share of the $14.9M market across 1,244 shipments from 97 exporters. The top 5 suppliers — ZYDUS LIFESCIENCES LIMITED, ALKEM LABORATORIES LIMITED, CADILA HEALTHCARE LIMITED, DR REDDYS LABORATORIES LIMITED, DR REDDY S LABORATORIES LIMITED — collectively control 91.2% of total export value, indicating a highly concentrated market. Individual shares are: ZYDUS LIFESCIENCES LIMITED (37.5%), ALKEM LABORATORIES LIMITED (28.5%), CADILA HEALTHCARE LIMITED (11.0%), DR REDDYS LABORATORIES LIMITED (9.5%), DR REDDY S LABORATORIES LIMITED (4.8%).
Top Sirolimus Exporters from India
Ranked by export value · 97 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | ZYDUS LIFESCIENCES LIMITED SIROLIMUS TABLETS 0.5 MG - 1 X 100PHARMA : SIROLIMUS TABLETS 0.5MG (SIROLISIROLIMUS TABLETS 0.5 MG - 1 X 100TBS | $5.6M | 2 | 37.5% |
| 2 | ALKEM LABORATORIES LIMITED SIROLIMUS TABLETS 0.5 MG - 1 X 100PHARMA : SIROLIMUS TABLETS 0.5MG (SIROLISIROLIMUS TABLETS 0.5 MG - 1 X 100TBS | $4.2M | 2 | 28.5% |
| 3 | CADILA HEALTHCARE LIMITED SIROLIMUS TABLETS 0.5 MG - 1 X 100PHARMA : SIROLIMUS TABLETS 0.5MG (SIROLISIROLIMUS TABLETS 0.5 MG - 1 X 100TBS | $1.6M | 1 | 11.0% |
| 4 | DR REDDYS LABORATORIES LIMITED SIROLIMUS TABLETS 0.5 MG - 1 X 100PHARMA : SIROLIMUS TABLETS 0.5MG (SIROLISIROLIMUS TABLETS 0.5 MG - 1 X 100TBS | $1.4M | 1 | 9.5% |
| 5 | DR REDDY S LABORATORIES LIMITED SIROLIMUS TABLETS 0.5 MG - 1 X 100PHARMA : SIROLIMUS TABLETS 0.5MG (SIROLISIROLIMUS TABLETS 0.5 MG - 1 X 100TBS | $708.6K | 1 | 4.8% |
| 6 | INTAS PHARMACEUTICALS LIMITED SIROLIMUS TABLETS 0.5 MG - 1 X 100PHARMA : SIROLIMUS TABLETS 0.5MG (SIROLISIROLIMUS TABLETS 0.5 MG - 1 X 100TBS | $282.7K | 1 | 1.9% |
| 7 | ALKEM LABORATORIES LTD SIROLIMUS TABLETS 0.5 MG - 1 X 100PHARMA : SIROLIMUS TABLETS 0.5MG (SIROLISIROLIMUS TABLETS 0.5 MG - 1 X 100TBS | $268.1K | 1 | 1.8% |
| 8 | GLENMARK PHARMACEUTICALS LIMITED SIROLIMUS TABLETS 0.5 MG - 1 X 100PHARMA : SIROLIMUS TABLETS 0.5MG (SIROLISIROLIMUS TABLETS 0.5 MG - 1 X 100TBS | $214.5K | 2 | 1.4% |
| 9 | CONCORD BIOTECH LTD SIROLIMUS TABLETS 0.5 MG - 1 X 100PHARMA : SIROLIMUS TABLETS 0.5MG (SIROLISIROLIMUS TABLETS 0.5 MG - 1 X 100TBS | $178.3K | 1 | 1.2% |
| 10 | DERRIC WOOD SIROMUS 1MG SIZE-6 TABS/PACKRAPACAN 1MG SIZE-10 TABS/PACSIROMUS 1MG SIZE-6 TABS/PACKS | $89.2K | 2 | 0.6% |
| 11 | CONCORD BIOTECH LIMITED SIROLIMUS TABLETS 0.5 MG - 1 X 100PHARMA : SIROLIMUS TABLETS 0.5MG (SIROLISIROLIMUS TABLETS 0.5 MG - 1 X 100TBS | $54.4K | 2 | 0.4% |
| 12 | SAMEEKSHA PHARMACEUTICALS PRIVATE LIMITED SIROLIMED 1 MGSIROBRU - SIROLIMUS TABLETS 1MG (PACK SISIROMAX TAB SIROLIMUS 1 MG | $18.8K | 1 | 0.1% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Sirolimus exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Zydus Lifesciences Limited | Warning Letter issued Nov | Yes, certified | Yes | 80+ FDA-approved generic products | FDA issued a Warning Letter in November 2019 for manufacturing violations; a Clo |
| Dr. Reddy's Laboratories Limited | Approved | Yes | Yes | Multiple FDA-approved generic products | Dr. Reddy's Laboratories has received FDA approvals for various generic products |
| Intas Pharmaceuticals Limited | Approved | Yes | Yes | Multiple FDA-approved generic products | Intas Pharmaceuticals has received FDA approvals for various generic products an |
| Cadila Pharmaceuticals Limited | Warning Letter issued Mar | Yes | Yes | Multiple FDA-approved generic products | FDA issued a Warning Letter in March 2014 for manufacturing violations at the An |
| Glenmark Pharmaceuticals Limited | Approved | Yes | Yes | Multiple FDA-approved generic products | Glenmark Pharmaceuticals has received FDA approvals for various generic products |
| Alkem Laboratories Limited | Approved | Yes | Yes | Multiple FDA-approved generic products | Alkem Laboratories has received FDA approvals for various generic products and m |
| Concord Biotech Limited | Approved | Yes | Yes | Multiple FDA-approved generic products | Concord Biotech has received FDA approvals for various generic products and main |
| Sameeksha Pharmaceuticals Private Limited | Approved | Yes | Yes | Multiple FDA-approved generic products | Sameeksha Pharmaceuticals has received FDA approvals for various generic product |
TransData Nexus reviewed the regulatory standing of 8 leading Sirolimus exporters from India. 6 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. 2 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Sirolimus sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as India's bulk drug capital, is renowned for its extensive production of active pharmaceutical ingredients (APIs). The city hosts numerous API manufacturers, contributing significantly to the country's pharmaceutical exports. Hyderabad's infrastructure supports large-scale API production, making it a pivotal hub for bulk drug manufacturing.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a prominent center for pharmaceutical formulations. Ahmedabad is home to major companies like Zydus Lifesciences Limited and Cadila Pharmaceuticals, both of which have substantial manufacturing facilities in the region. Vadodara complements this with its own pharmaceutical industries, contributing to the area's reputation as a formulations hub. The proximity to ports facilitates efficient export logistics, enhancing the region's appeal for pharmaceutical manufacturing.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical products. This region houses numerous pharmaceutical companies and benefits from well-established infrastructure, including proximity to major ports like Nhava Sheva. The concentration of corporate headquarters and regulatory affairs talent in this area further strengthens its role in facilitating pharmaceutical exports.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, initially attracting companies through tax incentives. The region hosts a multitude of pharmaceutical firms, contributing to its status as a major hub for drug production. Despite the phasing out of initial tax benefits, the established manufacturing ecosystem continues to support its prominence in the industry.
5Sourcing Recommendations
- Diversify Supplier Base: While Zydus Lifesciences Limited and Alkem Laboratories Limited are major exporters of Sirolimus, consider engaging with other manufacturers in different clusters to mitigate supply chain risks.
- Leverage Regional Specializations: Utilize Hyderabad's API production capabilities for bulk drug requirements and Ahmedabad-Vadodara's expertise in formulations for finished products.
- Optimize Logistics: Capitalize on the Mumbai-Thane-Raigad region's export infrastructure to streamline shipping processes and reduce lead times.
- Monitor Regulatory Compliance: Ensure all suppliers adhere to international quality standards and regulatory requirements to maintain product integrity and market access.
By strategically sourcing from these diverse pharmaceutical clusters, companies can enhance the resilience and efficiency of their Sirolimus supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Sirolimus exporters from India
Zydus Lifesciences Limited — Zydus acquires Agenus' CDMO business
In June 2025, Zydus Lifesciences Limited acquired the contract development and manufacturing organization (CDMO) business of Agenus, including two biologics manufacturing sites in Emeryville and Berkeley. This acquisition aims to enhance Zydus' biologics manufacturing capabilities. - IMPACT: This expansion may bolster Zydus' production capacity, potentially increasing Sirolimus exports.
Impact: This expansion may bolster Zydus' production capacity, potentially increasing Sirolimus exports.
Dr. Reddy's Laboratories Limited — Dr. Reddy's partners with Alvotech for biosimilar development
In June 2025, Dr. Reddy's Laboratories entered into a collaboration with Alvotech to co-develop a biosimilar candidate to Keytruda (pembrolizumab). This partnership focuses on oncology biosimilars. - IMPACT: While centered on oncology, this collaboration may enhance Dr. Reddy's expertise in biosimilars, indirectly benefiting Sirolimus production.
Impact: While centered on oncology, this collaboration may enhance Dr. Reddy's expertise in biosimilars, indirectly benefiting Sirolimus production.
Zydus Lifesciences Limited and Dr. Reddy's Laboratories Limited — Zydus and Dr. Reddy's co-market pharmaceutical products
In June 2024, Zydus Lifesciences and Dr. Reddy's Laboratories announced a licensing agreement for the co-marketing of certain pharmaceutical products. This strategic partnership aims to leverage both companies' strengths in the market. - IMPACT: This collaboration could lead to increased market reach and efficiency in Sirolimus distribution.
Impact: This collaboration could lead to increased market reach and efficiency in Sirolimus distribution.
Common Questions — Sirolimus Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which sirolimus supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, ZYDUS LIFESCIENCES LIMITED leads with 32 recorded shipments worth $5.6M. ALKEM LABORATORIES LIMITED (54 shipments) and CADILA HEALTHCARE LIMITED (5 shipments) are also established high-volume exporters.
Q How many sirolimus manufacturers are there in India?
India has 97 active sirolimus exporters with a combined export market of $14.9M across 1,244 shipments to 48 countries. The top 5 suppliers hold 91.2% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for sirolimus from India?
Average FOB unit price: $9.57 per unit, ranging from $0.03 to $928.80. Average shipment value: $12.0K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 97 verified Indian exporters of Sirolimus ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,244 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 48 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,244 Verified Shipments
97 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists